Postpartial gland cryoablation outcomes
| Catheter duration (days), median (IQR) | 6 (3–7) |
| PSA decrease from baseline (ng/ml), median (IQR) | 4.3 (2–6.2) |
| MRI findings | |
| % decrease in prostate volume from baseline, median (IQR) | 18.3 (0–28.0) |
| Max PI-RADS V.2, n (%) | |
| No lesions/not identified | 15 (48.40) |
| 2 | 2 (6.45) |
| 3 | 5 (16.13) |
| 4 | 7 (22.57) |
| 5 | 2 (6.45) |
| Post-treatment targeted biopsy (max GG), n (%) | |
| Benign | 15 (42.86) |
| 1 | 7 (20.0) |
| 2 | 11 (31.43) |
| 3 | 1 (2.86) |
| 4 | 1 (2.86) |
| Recurrence, n (%) | |
| In-field | 7 (20.00) |
| Out-of-field | 6 (17.14) |
| Ablated site | 10 (28.57) |
| Non-ablated site | 3 (8.57) |
| Post-treatment plan, n (%) | |
| Active surveillance | 24 (68.57) |
| Repeat PGC | 5 (14.29) |
| Radical prostatectomy | 3 (8.57) |
| Radiation treatment | 3 (8.57) |
GG, grade group; PGC, prostate gland cryoablation; PI-RADS V.2, Prostate Imaging-Reporting and Data System V.2; PSA, prostate specific antigen.